Emile van Corven appointed as Vice President Chemistry Manufacturing & Control (VP CMC)

TargED Biopharmaceuticals is very pleased to announce the appointment of Emile van Corven as their Vice President Chemistry Manufacturing & Control. Kristof Vercruysse, CEO commented: “In Emile, we found the ideal candidate to improve and standardize the production process of our lead compound, Microlyse.” Please… Read More »Emile van Corven appointed as Vice President Chemistry Manufacturing & Control (VP CMC)

HIRING – Scientific & Medical Writer

July 2022 – We’re currently looking for a Scientific & Medical Writer to strengthen our team. Are you looking for a new challenge and do you match our profile? Please make sure to send us your CV + motivation letter.

TargED raises €39 million in a series A investment round

TargED is extremely pleased and proud to have raised €39 million in a Series A investment round! Together with an international investor syndicate  we’ll pursue our common goal: to bring Microlyse into clinical development! Read the press release here

Microlyse as treatment for TTP published in Blood journal

January 2022 – Our new clot-buster Microlyse is now published in- and on the cover of Blood. You can: Listen to the Blood podcast (7:15 – 12:30)  Download our paper here (before March 18, 2022) click to enlarge

HIRED – TargED appoints Ludo Haazen,M.D. as Chief Medical Officer

June 2021 – TargED Biopharmaceuticals today announced the appointment of Ludo Haazen as Chief Medical Officer (CMO). With his extensive experience in the clinical development of new medical products, Ludo will support the company’s transition from preclinical to clinical stage company. 

TargED closes €1.35m seed investment round!

November 24th, 2020 – We are very proud to announce the closing of a €1.35m Seed investment from Curie Capital, Utrecht Health Seed Fund and Fonds InvesteringsRijpe STarts (FIRST), supported by additional funding from Health Holland. Pleas find the full press release attached!